INTRODUCTION
Allogeneic (allo-) bone marrow transplantation (BMT) is the only curative option for a number of malignant and non-malignant diseases. The utility of allo-BMT is limited by the development of acute graft versus host disease (aGVHD) [1] . Experimental and clinical data suggest that aGVHD is predominantly mediated by a Th1-type cytokine response [2, 3] , although an additive role for Th1 and Th2 cells has been described [4] . Interestingly, the production of Interleukin-13 (IL-13) by donor T cells responding to host antigens in vitro was recently shown to correlate with the severity of clinical aGVHD [5] . IL-13 is a typical Th2-type cytokine that is produced by a wide variety of cells including T cells [6, 7] . IL-13 binds to its functional receptor (IL-13R) that consists of the IL-4Ra chain and the IL-13Ra1 chain [8] or to a decoy receptor, called IL-13Ra2 [9] . IL-13 exhibits a range of biologic activities, some of which overlap with those observed with IL-4 [10] [11] [12] . Although T lymphocytes are a significant producer of IL-13, these cells do not express the IL-13R on their surface and therefore do not respond to this cytokine [13] . We used a well-established murine BMT model (BALB/cB6) and mice deficient in IL-13 as BMT donors to more clearly determine the role of donor T cell derived IL-13 in the pathogenesis of aGVHD.
MATERIAL AND METHODS

Mice and Bone Marrow Transplantation
Female BALB/c IL-13 þ/þ (H-2 d ) and C57BL/6 (H-2 b ) mice were purchased from Jackson Laboratories (Bar Harbor, ME). BALB/c IL-13
) mice were provided by Andrew McKenzie [14] . Animals were housed and fed as previously described [15] . Mice received BMT as described previously [16] . C57BL/6 mice received 13 Gy total body irradiation (TBI; 137 Cs source) split into two doses followed by intravenous injection of 5 Â 10 6 bone marrow (BM) and 2 Â 10 6 CD4þ and CD8þ magnetic-bead-purified (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) splenic T cells from either syngeneic B6, allogeneic BALB/c IL-13 þ/þ or allogeneic BALB/c IL-13 À/À donors. Survival was monitored daily until day 180.
Fluorescence-activated Cell Sorting (FACS) Analysis
Cells were analyzed by FACS using fluorescein isothiocyanateconjugated monoclonal antibodies to CD8 and phycoerythrinconjugated antibodies to CD4 (BD Pharmingen, San Diego, CA) as described [15] . 
T Cell Proliferation
Donor T cell expansion in the spleen was assessed in vivo 7 and 14 days following BMT as described [15] . Antigen-specific T cell proliferation in vitro was assessed in mixed lymphocyte reactions (MLR) [15] . C57BL/6, BALB/c IL-13 þ/þ or BALB/c IL-13 À/À T cells were plated at a concentration of 2 Â 10 5 cells/well with 2 Â 10 4 C57BL/6 splenic DCs isolated as described [15] . At 96 hr, supernatants were collected for cytokine analysis, responder cells were pulsed with 3 [H] thymidine and proliferation was determined 24 hr later on a 1205 Betaplate reader (Packard, Downers, Grove, IL). As a positive control, T cell proliferation in response to Concavalin A was also determined [15] . In some experiments, C57BL/6 peritoneal cells were pre-incubated with recombinant IL-13 (6 hr) or MLR supernatants (4 hr) prior to stimulation with lipopolysaccharide (LPS) to produce TNFa.
Measurement of Cytokine Protein Levels by ELISA
Concentrations of IFNg, IL-13 in serum (day þ7 after BMT) and/or cell culture supernatants were measured in duplicate by ELISA (IFNg: OptEIA; BD Pharmingen. IL-13: Biosource; Camarillo, CA). Serum levels of TNFa, IL-2,-4,-5 were determined by Cytokine Bead Array (Th1/Th2 cytokine kit, BD Pharmingen). Assay methods and limits of detection were followed as per the specific protocol.
Statistical Analysis
Values are expressed as the mean AE S.E.M. Statistical comparisons between groups were completed using the parametric independent sample t-test. Survival curves were plotted using Kaplan-Meier estimates. The log-rank test was used to analyze survival data.
RESULTS AND DISCUSSION
We investigated the role of IL-13 produced by donor cells in the pathogenesis of aGVHD. First, we determined whether the absence of IL-13 in T lymphocytes alters alloantigen-specific responses in vitro. C57BL/6, BALB/c IL- alloantigens compared to syngeneic controls (Supplemental Figure  1a) and only modest changes in IFNg (P < 0.05) and IL-2 (n.s.) production were seen in vitro but not in vivo between allogeneic groups (Supplemental Figure 1b and c) . While allogeneic wild-type T cells produced significant amounts of IL-13 in culture, IL-13 levels in MLRs using allogeneic IL-13 À/À T cells were low and did not differ from syngeneic controls (Supplemental Figure 1d) . Further, IL-5 (Supplemental Figure 1e) and IL-4 (not shown) production by IL-13 À/À T cells were also significantly reduced, indicating a general decrease in Th2 cytokine production. Consistent with previous reports [14] , similar results were obtained after nonspecific T cell stimulation with Con A (Supplemental Figure 1a- [17] . We hypothesized that the reduction in Th2 cytokine production following IL-13 À/À BMT would correlate with increased aGVHD severity. As shown in Figure 1a , 90% of recipients of allo-BMT from IL-13 À/À donors died of aGVHD by day 150. By contrast, animals receiving allo-BMT from IL-13 þ/þ donors showed a significant reduction in aGVHD mortality (P < 0.02). Mortality was associated with increased serum TNFa levels after allo-BMT, and TNFa levels were significantly higher after allo-BMT with IL-13À/À cells compared to recipients of allogeneic IL-13 þ/þ BMT (Fig. 1b) . We hypothesized that the enhanced mortality seen following allo-BMT with IL-13 À/À donors were secondary to the loss of the immunomodulatory effects of IL-13 on macrophage function and TNFa secretion [18] . To test this, we pre-incubated B6 peritoneal cells prior to LPS stimulation with either recombinant IL-13, or supernatants collected from MLRs using either IL-13 þ/þ or IL-13 À/À T cells. The latter design was chosen to reproduce in vitro, aspects of immune dysregulation that were occurring in vivo following allo-BMT. As shown in Figure 1c , the addition of recombinant IL-13 to cell culture prior to LPS stimulation resulted in a significant reduction in TNFa production by peritoneal cells in a dose-dependent fashion. Similar reductions were observed when peritoneal cells were pre-incubated with supernatants collected from MLRs using T cells capable of producing IL-13 (IL-13 þ/þ ) compared to the conditioned media collected from T cells that could not (Fig. 1d) . Collectively, these data suggest that donor derived IL-13 down-regulates TNFa production following allo-BMT. This effect in combination with the ability of IL-13 to augment the secretion of Th2 cytokines such as IL-4 or IL-5 or other immunomodulatory proteins like TGFb [19] [20] [21] may contribute to a protective role of IL-13 in aGVHD pathophysiology. The previously described correlation between the in vitro production of IL-13 by donor T cells and clinical aGVHD [5] offers an interesting approach to predict GVHD pre-transplant. However, since alloreactive T cells are a significant source of IL-13 (Supplemental Figure 1d) , this correlation may simply reflect the overall allo-activation status of these cells rather that a direct link between IL-13 and GVHD severity. While our data support this hypothesis, it is possible that IL-13 could directly enhance target organ injury in a Th2-mediated manner [4] . Whether proinflammatory effects of IL-13, such as those seen with airway hyperresponsiveness, eosinophilia and fibrosis [19, 22, 23] , play a functional role in chronic GVHD remains to be determined.
INTRODUCTION
Li-Fraumeni syndrome (LFS) is a rare familial cancer syndrome originally identified through analysis of rhabdomyosarcoma patients and their families [1] . Classic LFS is characterized by bone or soft tissue sarcoma before age 45 years in an individual with a first degree relative diagnosed with cancer before age 45, and one additional first or second degree relative diagnosed with cancer at an early age or sarcoma at any age [2] [3] [4] . Families that exhibit a clustering of LFS cancers but do not conform to all the features of classic LFS are labeled Li-Fraumeni-like (LFL) families. LFL syndrome is characterized by occurrence of a LFS-related cancer before age 45 years in an individual with two first or second degree relative with LFS-related malignancies [5] .
Germline mutations in the p53 tumor suppressor gene located on chromosome 17p13 have been identified in 70-80% of LFS families and in 20-40% of LFL families [2, 4, 6, 7] . Germline and somatic p53 mutations are similar, with the majority missense substitutions resulting in defective transcriptional regulation. Inactivating germline mutations in the p53 gene are highly penetrant and individuals harboring p53 mutations have an elevated risk for multiple primary cancers [8] . Here we report the identification of a novel p53 germline mutation in a child with pilocytic astrocytoma and leukemia, in a LFL family with a clustering of brain tumors.
CLINICAL REPORT
A previously healthy 2 1/2-year-old presented with a seizure. Brain MRI revealed a left parietal tumor. The tumor was completely resected and found to be a pilocytic astrocytoma (WHO grade I). No adjuvant therapy was necessary.
At age 4 years, she presented with pallor, hepatosplenomegaly, and fever. Peripheral blood white cell count was 21,800/mm 3 with 90% lymphoblasts. Bone marrow aspirate confirmed the diagnosis of B-progenitor cell acute lymphoblastic leukemia (ALL). Cytogenetic analysis identified the TEL/AML-1 fusion gene in lymphoblasts. There was no central nervous system disease. After two years of treatment per Pediatric Oncology Group protocols 9900 and 9904 regimen D, she is now on maintenance chemotherapy.
A family history revealed the death of the patient's father secondary to glioblastoma multiforme at age 46. The patient's paternal uncle died secondary to glioblastoma at age 48. The patient's mother is healthy. The maternal grandmother developed breast cancer at age 60, and died at age 61 from heart failure. A family pedigree is in Figure 1 . A diagnosis of LFL syndrome was considered. The mother consented to p53 genotyping for the patient
We describe a 2-year-old female with a completely resected cerebral pilocytic astrocytoma who subsequently developed Bprogenitor acute lymphoblastic leukemia (ALL). Her father and paternal uncle were previously diagnosed with glioblastoma multiforme. Sequence analysis of the patient's p53 gene revealed a novel germline three base-pair deletion (339_341delCTT) in exon 4, resulting in removal of an evolutionarily conserved phenylalanine amino acid residue at codon 113. The same mutation was found in the patient's two clinically unaffected siblings. The in-frame deletion we describe has not previously been reported and adds to our understanding of the biologic effects of p53 gene mutation 
